In�vitro effect of curcumin in combination with chemotherapy drugs in Ph+ acute lymphoblastic leukemia cells

Abstract

Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL), is characterized by the t(9;22)(q34q11) that generates the BCR-ABL protein with uncontrolled tyrosine kinase activity. Recently, a connection between BCR-ABL signaling with NF-κB activation mediated by CK2 has been hypothesized. Approximately 95% of patients with Ph + ALL have the BCR-ABLp190 isoform, which causes aggressive leukemia with a high rate of chemotherapy resistance. Therefore, the use of compounds that could improve the efficacy of chemotherapy drugs is of particular interest. Curcumin is an active chemical in turmeric with antineoplastic potential; it regulates protein-kinases by modulating downstream molecular pathways. The present study evaluated the effect of curcumin in combination with the chemotherapeutic drugs vincristine, imatinib and daunorubicin in the human OP-1 cell line. Several doses of the chemotherapy drugs were examined, and the effects were evaluated following 12, 24 and 48 h of exposure. The interaction between the chemotherapy drugs and curcumin was determined by the dose-effect curve, which generated a combination index (CI); these data were represented in isobolograms. In addition, the individual effect of each drug was compared with its effect in combination with curcumin on cell viability, apoptosis degree, NF-κB activation and gene expression changes. The present study observed that curcumin potentiates the efficacy of vincristine and imatinib, generating an additive/synergistic effect in a dose-and time-dependent manner. These combinations significantly increased the apoptosis degree, decreased the activation of NF-κB and the expression of its regulated genes. Conversely treatment with daunorubicin + curcumin combination produced an antagonistic/additive effect in a dose-dependent manner, and this combination significantly increased the apoptosis degree. However, this effect seems not to be associated with NF-κB activity, as no significant changes were observed in its activation or in the expression of the genes that it regulates. The results of the present study demonstrate that curcumin may be used as an adjuvant agent for chemotherapy in patients with Ph + ALL.

Complementary and Alternative Treatments for Cancer Prevention and Cure [Part 1]

“…Potentiates the efficacy of vincristine and imatinib, significantly increased the apoptosis degree, decreased the activation of NF-κB and the expression of its regulated genes [239].…”

Is Curcumin the Answer to Future Chemotherapy Cocktail?

“…Further investigations illustrated that curcumin (10 μM) with other chemotherapeutic agents, notably imatinib and vincristine, synergistically induced apoptosis via the downregulation of Bcl-2 and anti-angiogenesis effect via the downregulation of VEGF in ALL cells. Besides, combination treatment reversed the NF-κB activity induced by imatinib and vincristine [ 141 ]. Similarly, curcumin (40 μM) potentiated the inhibitory effect of thalidomide (80 μM) in acute myeloid leukemia cells KG-1 and U937 by downregulating the Bcl-xL expression in apoptosis and repressing STAT3 expression [ 142 ].…”